Interplay Between Fibroblast Growth Factor-19, Beta-Klotho and Receptors Impact Cardiovascular Risk in Chronic Kidney Disease
Authors:
- Laura González-RodríguezLGLaura González-Rodríguez
- Manuel Martí-AntonioMMManuel Martí-Antonio
- Virginia Díaz-AcevedoVDVirginia Díaz-Acevedo
- Sonia Mota-ZamoranoSMSonia Mota-Zamorano
- Celia ChicharroCCCelia Chicharro
- Bárbara CanchoBCBárbara Cancho
- Raquel Gil-LozanoRGRaquel Gil-Lozano
- Zoraida VerdeZVZoraida Verde
- Fernando BandrésFBFernando Bandrés
- Nicolás R. RoblesNRNicolás R. Robles
- Guillermo GervasiniGuillermo Gervasini
Preprint
- 19 December 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. In 579 CKD patients, plasma FGF19 and β-Klotho con-centrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1 and FGFR4 genes were analyzed. Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR=2.97 (1.12–7.92), p=0.029]. Two genetic variants also showed independent associa-tions: FGFR1 rs2288696 (protective) [HR=0.51 (0.27–0.95), p=0.029] and KLB rs2687971 (risk-increasing) [HR=2.03 (0.97–4.27), p=0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs and traditional risk factors achieved good discrimina-tive ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive im-portance comparable to diabetes and previous CV history. These findings suggest that in-tegrating FGF19-Klotho biomarkers with genetic information may enhance CV risk pre-diction in CKD.Keywords
All Related Versions
- Version 1, 2025-12-19, Preprints
- Published version: Journal of Clinical Medicine, 15 (3), 1005.
This publication has 46 references indexed in Scilit:
- Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patientsiScience, 2025
- Endothelin-1 as dual marker for renal function decline and associated cardiovascular complications in patients with chronic kidney diseaseEuropean Journal of Internal Medicine, 2025
- High plasma fibroblast growth factor 19 is associated with improved prognosis in patients with acute ischemic strokeClinical Nutrition, 2025
- Cardiovascular Risk Prediction Scores in Type 1 DiabetesJACC: Advances, 2024
- Targeted next-generation sequencing panel to investigate antiplatelet adverse reactions in acute coronary syndrome patients undergoing percutaneous coronary intervention with stentingThrombosis Research, 2024
- Updates on New Therapies for Patients with CKDKidney International Reports, 2023
- FGF21 and Chronic Kidney DiseaseMetabolism, 2021
- FGF19 subfamily members: FGF19 and FGF21Journal of Physiology and Biochemistry, 2019
- Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homoeostasis in the diabetic heartBiochemical and Biophysical Research Communications, 2018
- Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical studyActa Diabetologica, 2010